Get the latest news, insights, and market updates on IBRX (ImmunityBio, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
3 Stocks That Could Be Undervalued By Up To 49.7%
As the U.S. stock market reaches new heights with major indices like the S&P 500, Dow, and Nasdaq hitting record highs driven by a surge in technology stocks, investors are keenly exploring opportunities that may still be undervalued amidst this bullish trend. Identifying undervalued stocks requires a careful assessment of their intrinsic value compared to current market prices, especially in an environment where interest rates have been cut and tech investments are booming. Sep 19, 2025 - $IBRX
H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 10, H.C. Wainwright reiterated the Buy rating on ImmunityBio, Inc. (NASDAQ:IBRX), keeping the price target at $8. Andres Y. Maldonado from H.C. Wainwright reaffirmed the rating on IBRX after the company announced promising developments with […] Sep 15, 2025 - $IBRX
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
CULVER CITY, Calif., September 08, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced new paradigm changing findings from the Phase 2 QUILT-3.055 study, demonstrating ANKTIVA® (nogapendekin alfa inbakicept-pmln) reverses lymphopenia (low natural killer and T cells) in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer (NSCLC), with this reversal resulting in significant prolonged median overall survival (mOS). The results were p Sep 8, 2025 - $IBRX
A Closer Look at ImmunityBio (IBRX) Valuation Following Promising Early Results in Glioblastoma Study
If you have been eyeing ImmunityBio (IBRX) lately, the latest news might make you pause and take a closer look. The company just announced that its investigational immune-boosting regimen, which includes ANKTIVA, achieved disease control in all five of the first recurrent glioblastoma patients treated in a pilot study. For a disease this tough to treat, seeing every patient respond, even in a small group, is a rare milestone that has quickly caught investor attention. These early findings... Sep 6, 2025 - $IBRX
ImmunityBio (IBRX) Reports Initial Study Data Showing 100% Disease Control in Patients With Recurrent Glioblastoma
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best long-term penny stocks to buy right now. On August 26, ImmunityBio, Inc. (NASDAQ:IBRX) announced the early findings of the first five recurrent glioblastoma patients that were treated with its investigational immune-boosting regimen, including ANKTIVA, in this pilot study. The company reported that all five patients attained 100% disease […] Aug 31, 2025 - $IBRX
ImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield™ Platform
We recently published 10 Best Biotech Stocks to Buy Under $10. ImmunityBio, Inc. is among them. ImmunityBio, Inc. (NASDAQ:IBRX) is a commercial-stage biotechnology company developing next-generation immunotherapies and cell therapies to treat cancer and infectious diseases, and is among the best biotech stocks. Its lead product, ANKTIVA, is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer […] Aug 28, 2025 - $IBRX
What ImmunityBio (IBRX)'s Early Glioblastoma Disease Control Results Could Mean for Shareholders
ImmunityBio recently reported early results from a pilot study in recurrent glioblastoma, revealing that all five patients treated with its new combination immunotherapy regimen, anchored by ANKTIVA and combined with NK cell therapy and the Optune device, achieved disease control, including responses in participants with a condition known for poor treatment outcomes. This small cohort's complete disease control in such a challenging cancer has prompted the company to plan a Phase 2 trial,... Aug 27, 2025 - $IBRX
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
CULVER CITY, Calif., August 19, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored by ANKTIVA® (nogapendekin alfa inbakicept-pmln), in patients with long COVID. An estimated one in five Americans with a previous COVID-19 infection has long COVID, which is comprised of a broad range of symptoms that can substantially impact a patient’s quality of life. Long COVID remains a signific Aug 19, 2025 - $IBRX
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates
We recently published 12 Best Healthcare Stocks to Buy Under $30. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best healthcare stocks. ImmunityBio, Inc. (NASDAQ:IBRX) is among the best healthcare stocks. It is a clinical-stage biotech company developing advanced immunotherapies and vaccines targeting cancers and infectious diseases by activating immune cells such as natural killer and T […] Aug 17, 2025 - $IBRX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple